Stopping treatment to stay in remission for chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at stopping TKI treatment (a type of targeted therapy for CML) to see if you can stay in remission without medication. It is for people with CML in chronic phase who are either newly diagnosed or on a TKI but not achieving optimal results or not tolerating the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 14 years old or older.
- You must have Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase, either newly diagnosed or already on a TKI medication (like imatinib, nilotinib, dasatinib, or flumatinib) but not meeting treatment goals or having intolerable side effects.
- You must not have had a stem cell transplant before joining the study.
- If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before starting.
- You must not have a known T315I mutation (a specific genetic change that makes CML resistant to many treatments).
- You must not have another active cancer that needs treatment, and you must be able to follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
This study looks at whether people with chronic myeloid leukemia (CML) can safely lower their dose of targeted therapy before completely stopping it. It aims to see if a gradual reduction helps maintain long-term remission without the cancer coming back.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.